REPL
HealthcareReplimune Group, Inc.
$8.42
$-0.48 (-5.39%)
Jan 5, 2026
Price History (1Y)
Analysis
Replimune Group, Inc. is a biotechnology company in the healthcare sector with 479 employees and a market capitalization of $660.49 million. The company's financial health is marked by significant losses, as indicated by net income of -$310.26 million and EBITDA of -$312.95 million over the trailing twelve months. Free cash flow was also negative at -$161.47 million during this period. Notably, the gross margin, operating margin, and profit margin were all 0.0%, suggesting a lack of profitability. Replimune's valuation is characterized by a forward price-to-earnings ratio of -4.08 and an enterprise value to EBITDA multiple of -1.44, indicating that investors are currently paying negative prices relative to earnings and EBITDA. The company has $323.64 million in cash but also carries debt of $76.32 million, resulting in a debt-to-equity ratio of 28.98.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About Replimune Group, Inc.
Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of oncolytic immunotherapies to treat cancer. The company's proprietary oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF for a range of solid tumors. The company is also developing RP2 that express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3, which express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.
Visit website →Key Statistics
- Market Cap
- $660.49M
- P/E Ratio
- N/A
- 52-Week High
- $14.79
- 52-Week Low
- $2.68
- Avg Volume
- 4.11M
- Beta
- 0.73
Company Info
- Industry
- Biotechnology
- Exchange
- NMS
- Country
- United States
- Employees
- 479